Researchers Submit Patent Application, "Cancer Therapy", for Approval (USPTO 20240115684).
In: Cancer Vaccine Week, 2024-04-29, S. 157-157
serialPeriodical
Zugriff:
The article discusses a patent application for a cancer therapy developed by Richard Lesniewski and Doug McNeel. The therapy involves using a DNA vaccine to target the prostatic acid phosphatase (PAP) gene in prostate cancer, along with a human programmed death receptor-1 (PD-1) inhibitor to enhance the treatment's effectiveness. The method has shown promising results in early trials, with potential benefits including objective disease response, decline in serum prostate-specific antigen (PSA), and prolonged time to disease progression. The patent application emphasizes the importance of bioengineering and clinical research in the field of oncology, and explores the potential of combining synthetic vaccines with existing cancer treatments to improve patient outcomes. [Extracted from the article]
Copyright of Cancer Vaccine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Cancer Therapy", for Approval (USPTO 20240115684).
|
---|---|
Zeitschrift: | Cancer Vaccine Week, 2024-04-29, S. 157-157 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6810 (print) |
Schlagwort: |
|
Sonstiges: |
|